Sangamo BioSciences | SGMO - Selling And Administration Expenses

Stock Price
0.39
Daily Change
-0.01 -2.33%
Monthly
-3.50%
Yearly
-61.40%
Q1 Forecast
0.42

Sangamo BioSciences reported $9.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 585K 260K Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Amgen USD 1.94B 237M Dec/2025
Bayer EUR 4.05B 647M Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 1.23B 498M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Tectonic Therapeutic USD 4.96M 190K Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025